[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Sabel MS, Sondak VK: Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist; 2003;8(5):451-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pros and cons of adjuvant interferon in the treatment of melanoma.
  • Should interferon alpha (IFN-alpha) be considered the standard of care for the adjuvant therapy of high-risk malignant melanoma?
  • For 2003, it was estimated that 51,400 cases of invasive melanoma would be diagnosed.
  • The risk of recurrence after surgery is reported to be approximately 60% for patients with thick primary lesions (T4N0M0, American Joint Committee on Cancer [AJCC] stage IIB) and 75% for patients with regional nodal metastases (T1-4N1M0, AJCC stage III).
  • The observation that melanoma is susceptible to attack by the host's immune system has resulted in the testing of a remarkably broad spectrum of immunotherapies in the adjuvant setting.
  • This roller coaster has left many clinicians still hesitant to strongly recommend it, and the use of adjuvant IFN-alpha in high-risk melanoma remains controversial.
  • This manuscript reviews the leading arguments for and against its routine use and addresses questions regarding its role in the management of high-risk malignant melanoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Immunotherapy. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncologist. 2003;8(5):448-50 [14530497.001]
  • (PMID = 14530498.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  • [Number-of-references] 27
  •  go-up   go-down


2. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE: Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res; 2007 Apr 15;13(8):2422-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.
  • PURPOSE: Interferon (IFN)-alpha2b is the only Food and Drug Administration-approved treatment for operable high-risk melanoma that has been shown to significantly and durably prolong relapse-free survival (RFS) of patients with stage IIB-III melanoma.
  • Development of reliable serum assays may contribute to the development of methods for earlier detection of melanoma and the selection of patients who may be most susceptible to current available interventions with IFNalpha.
  • EXPERIMENTAL DESIGN: A powerful high-throughput xMAP multiplex immunobead assay technology (Luminex Corp., Austin, TX) was used to simultaneously test 29 cytokines, chemokines, angiogenic as well as growth factors, and soluble receptors in the sera of 179 patients with high-risk melanoma and 378 healthy individuals.
  • RESULTS: Serum concentrations of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-8, IL-12p40, IL-13, granulocyte colony-stimulating factor, monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, IFNalpha, tumor necrosis factor (TNF)-alpha, epidermal growth factor, vascular endothelial growth factor (VEGF), and TNF receptor II were found to be significantly higher in patients with resected high-risk melanoma compared with healthy controls.
  • Bayesian Network algorithm classification of the data offered 90% sensitivity at 98% specificity with 96.5% of melanoma patients distinguished from healthy individuals.
  • IFN-alpha2b therapy resulted in a significant decrease of serum levels of immunosuppressive and tumor angiogenic/growth stimulatory factors (VEGF, epidermal growth factor, and hepatocyte growth factor) and increased levels of antiangiogenic IFN-gamma inducible protein 10 (IP-10) and IFN-alpha.
  • CONCLUSION: These data show that multiplexed analysis of serum biomarkers is useful for the evaluation of prognostic markers of clinical outcome and potential predictive markers of response to IFN-alpha2b in patients with high-risk operable melanoma.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17438101.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / R01 CA108990
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytokines; 0 / Interferon-alpha; 0 / Interleukins; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


3. Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, Sian S, Lee PP: Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer; 2003 Jan 1;97(1):186-200
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
  • BACKGROUND: Forty-eight patients with resected Stages IIA and IIB melanoma were immunized with two tumor antigen epitope peptides derived from gp100(209-217) (210M) (IMDQVPSFV) and tyrosinase(368-376) (370D) (YMDGTMSQV) emulsified with incomplete Freund's adjuvant (IFA).
  • Time to recurrence and survival were secondary end points.
  • A leukapheresis to obtain peripheral blood mononuclear cells for immune analyses and skin testing with peptides and recall reagents was performed before and after eight vaccinations.
  • Seventeen of the 40 patients for whom posttreatment skin tests were performed developed a positive skin test response to the gp100 peptide, but only 1 of the 40 patients developed a positive skin test response to tyrosinase.
  • CONCLUSION: These data suggest a significant number of patients with resected melanoma mount an antigen-specific immune response against a peptide vaccine.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Neoplasm / immunology. Antibody Formation. Cytokines / immunology. Drug Therapy, Combination. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Membrane Glycoproteins / immunology. Middle Aged. Monophenol Monooxygenase / immunology. Neoplasm Proteins / immunology. Neoplasm Staging. Oligopeptides / immunology. T-Lymphocytes / immunology. Vaccination. gp100 Melanoma Antigen

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 12491520.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5P30 CA 14089; United States / NCI NIH HHS / CA / R01 CA 090809
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Cancer Vaccines; 0 / Cytokines; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / Oligopeptides; 0 / PMEL protein, human; 0 / gp100 Melanoma Antigen; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


Advertisement
4. Gogas H, Kirkwood JM, Falk CS, Dafni U, Sondak VK, Tsoutsos D, Stratigos A, Markopoulos C, Pectasides D, Spyropoulou-Vlachou M: Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer; 2010 Sep 15;116(18):4326-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon.
  • BACKGROUND: Interferon is approved for adjuvant treatment of patients with stage IIB/III melanoma.
  • Specific human leukocyte antigen (HLA) class I and II antigens have previously shown an association with response to therapy or overall survival of patients with metastatic melanoma.
  • METHODS: A total of 284 high-risk melanoma patients participating in a randomized trial and 246 healthy controls were molecularly typed for HLA class I and II.
  • RESULTS: No significant differences were found between the distribution of HLA genotype in the melanoma population compared with healthy controls.
  • Correlations between nonrecurrence and the presence of HLA-Cw 06 allele were noted present in 19.3% of melanoma patients.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Cancer Society.
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2444-58 [10856105.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):939-44 [19139440.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2370-80 [11331315.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3622-34 [11504744.001]
  • [Cites] Ann Surg Oncol. 2002 Jul;9(6):587-93 [12095976.001]
  • [Cites] Acta Derm Venereol. 2002;82(2):90-3 [12125959.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):1101-12 [12209697.001]
  • [Cites] Hum Immunol. 2002 Dec;63(12):1213-68 [12480266.001]
  • [Cites] Cancer Treat Rev. 2003 Aug;29(4):241-52 [12927565.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1670-7 [15014018.001]
  • [Cites] Tissue Antigens. 2004 Jul;64(1):84-7 [15191529.001]
  • [Cites] Hum Hered. 1978;28(3):171-200 [649177.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Aug;86(16):6230-4 [2762325.001]
  • [Cites] Immunol Today. 1991 Aug;12(8):267-70 [1910448.001]
  • [Cites] Tissue Antigens. 1991 May;37(5):197-204 [1685264.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6561-6 [1423301.001]
  • [Cites] Tissue Antigens. 1994 Jan;43(1):18-27 [8023317.001]
  • [Cites] Melanoma Res. 1994 Jun;4(3):191-4 [7919965.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):510-3 [7960221.001]
  • [Cites] Ther Immunol. 1995 Feb;2(1):1-6 [7553066.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):7-17 [8558223.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1995 Nov;18(4):242-52 [8680652.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):758-63 [8756369.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1430-7 [9552048.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):709-18 [16481638.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2422-8 [17438101.001]
  • [Cites] Adv Immunol. 2008;99:165-209 [19117535.001]
  • [Cites] N Engl J Med. 2000 Sep 14;343(11):782-6 [10984567.001]
  • (PMID = 20549830.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50CA121973
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  • [Other-IDs] NLM/ PMC2970916
  •  go-up   go-down


5. Gogas H, Dafni U, Koon H, Spyropoulou-Vlachou M, Metaxas Y, Buchbinder E, Pectasides E, Tsoutsos D, Polyzos A, Stratigos A, Markopoulos C, Panagiotou P, Fountzilas G, Castana O, Skarlos P, Atkins MB, Kirkwood JM: Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. J Transl Med; 2010 Nov 03;8:108
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial.
  • PURPOSE: Interferon is approved for adjuvant treatment of patients with stage IIb/III melanoma.
  • Predictive biomarkers that would enable selection of patients for therapy would have a large impact upon clinical practice.
  • Specific CTLA-4 polymorphisms have previously shown an association with response to CTLA-4 blockade in patients with metastatic melanoma and the development of autoimmunity.
  • EXPERIMENTAL DESIGN: 286 melanoma patients and 288 healthy controls were genotyped for six CTLA-4 polymorphisms previously suggested to be important (AG 49, CT 318, CT 60, JO 27, JO30 and JO 31).
  • RESULTS: No significant differences were found between the distributions of CTLA-4 polymorphisms in the melanoma population compared with healthy controls.
  • CONCLUSION: No polymorphisms of CTLA-4 defined by the SNPs studied were correlated with improved RFS, OS, or autoimmunity in this high-risk group of melanoma patients.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 May 15;164(10):5015-8 [10799854.001]
  • [Cites] Cancer. 2010 Sep 15;116(18):4326-33 [20549830.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2370-80 [11331315.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3477-82 [11481353.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):1101-12 [12209697.001]
  • [Cites] Nature. 2003 May 29;423(6939):506-11 [12724780.001]
  • [Cites] Scand J Immunol. 2003 Jun;57(6):568-72 [12791095.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 [12826605.001]
  • [Cites] J Hum Genet. 2004;49(3):166-8 [14986169.001]
  • [Cites] J Am Acad Dermatol. 1983 Nov;9(5):689-96 [6643767.001]
  • [Cites] Arch Dermatol. 1987 Aug;123(8):1053-5 [3631983.001]
  • [Cites] N Engl J Med. 1988 Jun 16;318(24):1557-63 [3259674.001]
  • [Cites] Eur J Immunol. 1988 Dec;18(12):1901-5 [3220103.001]
  • [Cites] Eur J Cancer. 1990;26(11-12):1152-6 [2149997.001]
  • [Cites] Dermatologica. 1991;183(4):239-45 [1809584.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1376-83 [8315436.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1621-4 [8156489.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):7-17 [8558223.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1995 Nov;18(4):272-8 [8680655.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1996 Jan;19(1):81-4 [8859727.001]
  • [Cites] Immunity. 1997 Oct;7(4):445-50 [9354465.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):741-50 [15613700.001]
  • [Cites] Immunol Rev. 2005 Apr;204:102-15 [15790353.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6043-53 [16087944.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):709-18 [16481638.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Mar;91(3):1087-92 [16352685.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2422-8 [17438101.001]
  • [Cites] Blood. 2007 Jul 1;110(1):461-7 [17384200.001]
  • [Cites] Clin Exp Immunol. 2007 Dec;150(3):487-93 [17924973.001]
  • [Cites] J Immunother. 2008 Jul-Aug;31(6):586-90 [18528295.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):939-44 [19139440.001]
  • [Cites] Genes Immun. 2000 Feb;1(3):170-84 [11196709.001]
  • (PMID = 21044351.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA93683; United States / NCI NIH HHS / CA / P50CA121973
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / DNA Primers; 9008-11-1 / Interferons
  • [Other-IDs] NLM/ PMC2988721
  •  go-up   go-down


6. Kirkwood JM, Moschos S, Wang W: Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin Cancer Res; 2006 Apr 1;12(7 Pt 2):2331s-2336s
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations.
  • Adjuvant trials have evaluated the influence of multiple agents on relapse and mortality for patients with intermediate-risk (stage IIA, American Joint Committee on Cancer staging manual, 6th ed.
  • ), high-risk (stage IIB-III), or very high-risk (stage IIIB-IV) operable melanoma.
  • A 25% to 33% reduction of relative relapse risk with high-dose IFN-alpha2b therapy has been documented in stage groups overall, with survival prolongation in two of these trials.
  • In contrast, no large cooperative group trial has ever shown a significant prolongation of survival for inoperable advanced stage IV melanoma.
  • The basis for the failure of therapies in advanced disease may lie in differences in the immune function of patients with active metastatic stage IV disease.
  • These observations argue for the exploration of promising new therapies in adjuvant settings.
  • Past adjuvant studies have targeted stage IIB-III patients, focusing less on the more advanced but resectable stage IIIB and IV (M(1a-b)) disease groups.
  • Predictive markers that would allow us to focus treatment on those patients who are most likely to respond would accelerate our development of adjuvant therapy for melanoma.
  • We have recently developed a neoadjuvant approach to high-dose IFN in which the molecular and immunologic effects of IFN have been correlated with clinical antitumor effects of this therapy.
  • These new insights will allow us to develop more efficient approaches to adjuvant therapy of melanoma, focusing on autoimmunity and antitumor immunity with new immunomodulators, such as anti-CTLA4 antibodies and vaccination.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Cancer Vaccines / therapeutic use. Cytokines / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16609054.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cancer Vaccines; 0 / Cytokines
  • [Number-of-references] 7
  •  go-up   go-down


7. Richtig E, Soyer HP, Posch M, Mossbacher U, Bauer P, Teban L, Svolba G, Wolf IH, Fritsch P, Zelger B, Volc-Platzer B, Gebhart W, Mischer P, Steiner A, Pachinger W, Hintner H, Gschnait F, Rappersberger K, Pilarski P, Pehamberger H, European Cooperative Adjuvant Melanoma Treatment Study Group: Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group. J Clin Oncol; 2005 Dec 1;23(34):8655-63
Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
  • PURPOSE: The combination of interferon alfa (IFNalpha) and isotretinoin has shown a direct antiproliferative effect on human melanoma cell lines, but it remained unclear whether this combination is more effective than IFNalpha alone in patients with metastatic melanoma.
  • We evaluated safety and efficacy of IFNalpha and isotretinoin compared with IFNalpha alone as adjuvant treatment in patients with primary malignant melanoma stage IIA and IIB.
  • PATIENTS AND METHODS: In a prospective, randomized, double-blind, placebo-controlled trial, 407 melanoma patients in stage IIA (301 patients) and IIB (106 patients) were randomly assigned to either IFNalpha and isotretinoin (isotretinoin group; 206 patients) or IFNalpha and placebo (placebo group; 201 patients) after excision of the primary tumor.
  • IFNalpha was administered three times a week at a dose of 3 million units subcutaneously for 24 months.
  • CONCLUSION: The addition of isotretinoin to an adjuvant treatment of low-dose IFNalpha in patients with stage IIA and IIB melanoma had no significant effect on disease-free or overall survival and is therefore not recommended.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Head and Neck Neoplasms / drug therapy. Interferon-alpha / therapeutic use. Isotretinoin / therapeutic use. Melanoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Chemotherapy, Adjuvant. Disease-Free Survival. Double-Blind Method. Europe. Female. Humans. Hyperlipidemias / chemically induced. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Prospective Studies. Quality of Life. Skin Diseases / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Dec 1;23(34):8559-63 [16260699.001]
  • (PMID = 16260701.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; EH28UP18IF / Isotretinoin
  •  go-up   go-down


8. Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJ, Delauney M, Sales F, Groenewegen G, Ruiter DJ, Jagiello I, Stoitchkov K, Keilholz U, Lienard D, EORTC Melanoma Group: Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet; 2005 Oct 1;366(9492):1189-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
  • BACKGROUND: Individuals affected by melanoma with thick primary tumours or regional node involvement have a poor outlook, with only 30-50% alive at 5 years.
  • High-dose and low-dose interferon alfa have been assessed for the treatment of these patients, with the former having considerable toxicity and a consistent effect on disease free survival, but not on overall survival, and the latter no consistent effect on either.
  • METHODS: We did a randomised controlled trial in 1388 patients who had had a thick primary tumour (thickness > or = 4 mm) resected (stage IIb) or regional lymph node metastases dissected (stage III) and had been assigned to 13-months (n=553) or 25 months (n=556) of treatment with subcutaneous interferon alfa 2b, or observation (n=279).
  • Treatment comprised 4 weeks of 10 million units (MU) of interferon alfa (5 days per week) followed by either 10 MU three times a week for 1 year or 5 MU three times a week for 2 years, to a total dose of 1760 MU.
  • Toxicity was acceptable, with 18% (195 of 1076) of patients going off study because of toxicity or as a result of refusal of treatment because of side-effects.
  • INTERPRETATION: Interferon alfa as used in the regimens studied does not improve outcome for patients with stage IIb/III melanomas, and cannot be recommended.
  • With respect to efficacy of the drug, duration of treatment seemed more important than dose, and should be assessed in future trials.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16198768.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10 CA11488-2; United States / NCI NIH HHS / CA / 5U10 CA11488-26; United States / NCI NIH HHS / CA / 5U10 CA11488-27; United States / NCI NIH HHS / CA / 5U10 CA11488-28; United States / NCI NIH HHS / CA / 5U10 CA11488-30; United States / NCI NIH HHS / CA / 5U10 CA11488-31; United States / NCI NIH HHS / CA / 5U10 CA11488-32; United States / NCI NIH HHS / CA / 5U10 CA11488-33; United States / NCI NIH HHS / CA / 5U10 CA11488-34; United States / NCI NIH HHS / CA / 5U10 CA11488-35
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


9. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol; 2001 May 01;19(9):2370-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.
  • PURPOSE: Vaccine alternatives to high-dose interferon alfa-2b therapy (HDI), the current standard adjuvant therapy for high-risk melanoma, are of interest because of toxicity associated with HDI.
  • The GM2 ganglioside is a well-defined melanoma antigen, and anti-GM2 antibodies have been associated with improved prognosis.
  • PATIENTS AND METHODS: Eligible patients had resected stage IIB/III melanoma.
  • RESULTS: Eight hundred eighty patients were randomized (440 per treatment group); 774 patients were eligible for efficacy analysis.
  • HDI was associated with a treatment benefit in all subsets of patients with zero to > or = four positive nodes, but the greatest benefit was observed in the node-negative subset (RFS HR = 2.07; OS HR = 2.71 [eligible population]).
  • CONCLUSION: This trial demonstrated a significant treatment benefit of HDI versus GMK in terms of RFS and OS in melanoma patients at high risk of recurrence.
  • [MeSH-major] Cancer Vaccines / immunology. G(M2) Ganglioside / immunology. Interferon-alpha / therapeutic use. Melanoma / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2002 Apr 15;20(8):2208; author reply 2209-10 [11956283.001]
  • [CommentIn] J Clin Oncol. 2001 Sep 1;19(17):3794 [11533109.001]
  • [CommentIn] J Clin Oncol. 2001 Dec 1;19(23):4350 [11731522.001]
  • (PMID = 11331315.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 39229-16; United States / NCI NIH HHS / CA / R03 CA75950-02
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / Saponins; 0 / Vaccines, Conjugate; 141256-04-4 / QS 21; 19600-01-2 / G(M2) Ganglioside; 43K1W2T1M6 / interferon alfa-2b; 9013-72-3 / Hemocyanin; FV4Y0JO2CX / keyhole-limpet hemocyanin
  •  go-up   go-down


10. Takada K, Kato J, Kawano Y, Takahashi S, Hayashi T, Ishiwatari H, Miyanishi K, Takimoto R, Kobune M, Sagawa T, Sato T, Sato Y, Yamashita T, Natori H, Niitsu Y: [Effective CDDP arterial infusion with DSM for liver metastasis of malignant melanoma complicating DIC due to intratumoral hemorrhage--a case report]. Gan To Kagaku Ryoho; 2008 Oct;35(10):1803-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effective CDDP arterial infusion with DSM for liver metastasis of malignant melanoma complicating DIC due to intratumoral hemorrhage--a case report].
  • A 65-year-old male, who had been diagnosed with melanoma of stage IIB and treated by chemotherapy since 2003 at the Dermatology Department, was referred to our department for liver metastasis of melanoma that had become resistant to chemotherapeutic agents.
  • Taken together, attention has to be paid to the potential for emergency complications of DIC due to liver metastasis of melanoma with intratumoral hemorrhage.
  • Moreover, it was shown that arterial infusion with DSM was effective for liver metastasis of melanoma.
  • [MeSH-major] Cerebral Hemorrhage / etiology. Cisplatin / therapeutic use. Disseminated Intravascular Coagulation / drug therapy. Disseminated Intravascular Coagulation / etiology. Liver Neoplasms / drug therapy. Melanoma / complications. Melanoma / drug therapy
  • [MeSH-minor] Aged. Humans. Infusions, Intra-Arterial. Male. Microspheres. Starch. Treatment Failure

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18931594.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 9005-25-8 / Starch; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Eggermont AM: Critical appraisal of IFN-alpha-based adjuvant therapy in stage II-III malignant melanoma. Expert Rev Anticancer Ther; 2002 Oct;2(5):563-9
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical appraisal of IFN-alpha-based adjuvant therapy in stage II-III malignant melanoma.
  • Interferon-alpha is a pleiotropic cytokine that has been extensively evaluated in the adjuvant setting for patients with Stage II-III melanoma in spite of a lack of efficacy or proof that interferon-alpha treatment improves survival in Stage IV melanoma.
  • Adjuvant therapy with interferon-alpha has a consistent effect on disease-free survival in the overall trial experience in melanoma patients with an intermediate (Stage II) or high risk (Stage IIB-III) for relapse of malignant melanoma.
  • In the absence of a clear indication that interferon-alpha therapy has an impact on survival, whereas important toxicity is associated with tumor necrosis factor-based treatment, interferon-alpha adjuvant therapy cannot be considered standard treatment.
  • It is too early for definitive analysis of the three largest trials and thus the mature results of these trials must be awaited.
  • Since the impact of dose and duration of treatment also awaits further evaluation.
  • It is reasonable to state that the role of interferon in melanoma still remains to be defined.
  • [MeSH-major] Clinical Trials, Phase III as Topic. Interferon-alpha / therapeutic use. Melanoma / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant / adverse effects. Humans. Meta-Analysis as Topic. Neoplasm Staging. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12382524.001).
  • [ISSN] 1473-7140
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon-alpha
  • [Number-of-references] 43
  •  go-up   go-down


12. Mohr P, Weichenthal M, Hauschild A: Adjuvant therapy in melanoma. Onkologie; 2003 Jun;26(3):227-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy in melanoma.
  • Despite intensive research and numerous clinical trials on the adjuvant treatment of patients with high-risk cutaneous melanoma, the issue is still controversial.
  • The effect of interleukin-2 in the adjuvant treatment of malignant melanoma is not yet clearly defined.
  • Combined treatment modalities like bio-chemotherapy are still to be analyzed in controlled clinical trials, and results of new studies with active specific immunization (vaccination) will only be available within the next years.
  • Only interferon alpha (IFN alpha) has shown reproducible superiority over observation for high-risk melanoma patients in large prospective randomized trials with respect to disease-free survival (DFS) and partially for overall survival (OS).
  • These studies resulted in the approval of IFN alpha for the adjuvant treatment of malignant melanoma in many countries.
  • The question whether high-dose IFN has shown enough superiority over observation with respect to OS based on one negative and two positive trials to make it the standard therapy in stage IIb,c and stage III melanoma patients still remains unanswered.
  • In conclusion, interferon is the cornerstone of adjuvant therapy in high-risk melanoma today, but the optimal dosage and duration of treatment are still to be defined.
  • Patients with high-risk malignant melanoma should preferentially be treated in prospective randomized multicenter trials to give more detailed data for treatment recommendations.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Neoplasm Staging. Randomized Controlled Trials as Topic. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger GmbH, Freiburg
  • (PMID = 12845206.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  • [Number-of-references] 51
  •  go-up   go-down


13. Kadison AS, Morton DL: Immunotherapy of malignant melanoma. Surg Clin North Am; 2003 Apr;83(2):343-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy of malignant melanoma.
  • Several areas of immunotherapeutic research may ultimately improve the effectiveness of active specific immunotherapy for melanoma and other malignancies.
  • The use of DNA vaccines to deliver nucleotides that encode relevant antigens and immunologic molecules, such as costimulatory molecules, and the use of targeted therapy with immunocytokines have yielded promising results in animal studies.
  • Although IFN-alpha 2b is the only FDA-approved adjuvant treatment for AJCC stage IIB/III melanoma, recent data failed to show a benefit in overall survival.
  • For patients with AJCC stage IV melanoma, chemotherapy with dacarbazine is currently the standard of care, with modest response rates of 15% to 20%.
  • The encouraging response rates and low toxicities that were reported in phase I/III trials suggest that active immunotherapy may prove to be the most effective adjuvant therapy.
  • At present, there are no FDA-approved cancer vaccines for malignant melanoma, and the results of ongoing randomized phase III clinical trials are greatly anticipated.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Immunotherapy. Melanoma / immunology. Melanoma / therapy. Skin Neoplasms / immunology. Skin Neoplasms / therapy
  • [MeSH-minor] Clinical Trials as Topic. Disease-Free Survival. Humans. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12744613.001).
  • [ISSN] 0039-6109
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA12582; United States / NCI NIH HHS / CA / CA76489
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Canvaxin
  • [Number-of-references] 153
  •  go-up   go-down


14. Groenewegen G, Osanto S, van der Rhee HJ, Punt CJ: [Interferon for adjuvant therapy in melanoma; although approved, not indicated]. Ned Tijdschr Geneeskd; 2000 Nov 4;144(45):2160-2
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interferon for adjuvant therapy in melanoma; although approved, not indicated].
  • [Transliterated title] Interferon als adjuvante therapie bij het melanoom: wel geregistreerd, niet geïndiceerd.
  • The Dutch melanoma group reconsidered their 1997 consensus statement on treatment of melanoma because new studies on adjuvant treatment with interferon(IFN)-alpha have been published.
  • These have resulted in its registration for stage IIa; for stage IIb/III IFN-alpha was already registered.
  • Overall survival should be the main endpoint of adjuvant clinical studies, especially when treatment is associated with toxicity.
  • Since a benefit has not been unequivocally demonstrated in melanoma with Breslow thickness > 1.5 mm and/or regional lymph node metastases, there is no need to change the Dutch consensus statement.
  • Drug registration authorities and medical professionals should cooperate more closely.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Melanoma / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Drug Approval. Humans. Lymphatic Metastasis. Neoplasm Staging. Netherlands. Practice Guidelines as Topic. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ned Tijdschr Geneeskd. 2001 Mar 10;145(10):498-9 [11268915.001]
  • (PMID = 11086492.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a
  • [Number-of-references] 8
  •  go-up   go-down


15. Feigl B, Faschinger C, Soyer P: Melanoma-associated retinopathy versus abnormal retinal function due to interferon-alpha/Isotretinoin therapy in cutaneous malignant melanoma. Ophthalmologica; 2000;214(4):271-6
Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma-associated retinopathy versus abnormal retinal function due to interferon-alpha/Isotretinoin therapy in cutaneous malignant melanoma.
  • PURPOSE: To analyze whether an abnormal retinal function in patients with a cutaneous malignant melanoma was due to paraneoplastic retinopathy or due to isotretinoin or interferon-alpha.
  • METHODS: We studied 15 patients with malignant melanoma in stage IIa and IIb who are all participants in a randomized, multicentered, double-blind placebo-controlled clinical trial comparing interferon-alpha/isotretinoin versus interferon-alpha/placebo performed by the Department of Dermatology, University of Graz.
  • In 1 patient the therapy was stopped because of electrophysiological and psychophysiological pathology.
  • CONCLUSIONS: We postulate that in 1 of 15 patients, visual complaints are caused with a high probability by melanoma-associated retinopathy although, in the literature, isotretinoin is described to show similar effects on retinal function.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Interferon-alpha / adverse effects. Isotretinoin / adverse effects. Melanoma / drug therapy. Paraneoplastic Syndromes / etiology. Retinal Diseases / chemically induced. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Color Perception. Double-Blind Method. Drug Therapy, Combination. Electroretinography. Female. Humans. Male. Night Blindness / etiology. Night Blindness / physiopathology. Prognosis. Visual Acuity. Visual Fields

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel.
  • (PMID = 10859510.001).
  • [ISSN] 0030-3755
  • [Journal-full-title] Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde
  • [ISO-abbreviation] Ophthalmologica
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; EH28UP18IF / Isotretinoin
  •  go-up   go-down


16. McMasters KM, Swetter SM: Current management of melanoma: benefits of surgical staging and adjuvant therapy. J Surg Oncol; 2003 Mar;82(3):209-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of melanoma: benefits of surgical staging and adjuvant therapy.
  • Issues regarding appropriate management of stage I to III melanoma are addressed.
  • Accurate surgical staging is critical to identifying patients who can benefit from therapeutic lymph node dissection and adjuvant therapy.
  • Patients with primary tumors > or = 1 mm thick are appropriate candidates for sentinel lymph node biopsy, and node-positive patients benefit from therapeutic lymphadenectomy.
  • Although the overall survival benefit of high-dose interferon has been questioned, the weight of evidence supports the use of adjuvant therapy in patients with stage IIB and III disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Melanoma / surgery. Neoplasm Staging / methods. Skin Neoplasms / surgery
  • [MeSH-minor] Biopsy. Chemotherapy, Adjuvant. Dose-Response Relationship, Drug. Humans. Lymph Node Excision. Prognosis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12619066.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  • [Number-of-references] 54
  •  go-up   go-down


17. Noorda EM, Vrouenraets BC, Nieweg OE, van Geel AN, Eggermont AM, Kroon BB: Prognostic factors for survival after isolated limb perfusion for malignant melanoma. Eur J Surg Oncol; 2003 Dec;29(10):916-21
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for survival after isolated limb perfusion for malignant melanoma.
  • METHODS: All of 439 patients who underwent ILP for melanoma of the extremities were studied.
  • Ninety percent of the patients had MD Anderson stage IIB or III disease at the time of ILP.
  • RESULTS: Sixty-nine patients died within this period, 64 of metastatic melanoma.
  • The indication for ILP was an unresectable primary (n=3), a local recurrence (n=24) or adjuvant to excision of primary lesions (n=17) in patients with stage IIIB regional lymph node metastases.
  • These patients or patients with stage IIIAB melanoma with satellites and/or in-transit metastases with regional lymph node metastases had a relative risk of 4.6 (95% CI 2.0-6.6) and 3.6 (95% CI 2.1-10) of dying within 1 year from ILP, respectively (p<0.001).
  • In patients with stage IV disease (distant metastases), the relative risk was 22 (95% CI 3.8-127, p=0.001).
  • CONCLUSION: Patients with advanced limb melanoma have an increased risk of death within 1 year after ILP when regional lymph node or distant metastases are present.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion / methods. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Extremities. Female. Humans. Hyperthermia, Induced. Logistic Models. Male. Melphalan / administration & dosage. Middle Aged. Prognosis. Risk Factors. Survival Analysis. Treatment Outcome. Tumor Necrosis Factor-alpha / administration & dosage

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14624788.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


18. Muggiano A, Mulas C, Fiori B, Liciardi G, Pintus M, Tanca L, Tedde A, Turno R, Desogus A: Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma. Melanoma Res; 2004 Apr;14(2):S1-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.
  • The Kirkwood high-dose interferon-alpha2b adjuvant therapy in high-risk-of-recurrence melanoma patients (stage IIb-III) demonstrated a benefit in terms of disease-free survival (DFS) (three trials out of three) and overall survival (OS) (two trials out of three).
  • This problem is the most limiting of this treatment.
  • The aim of the study was to check these results and the feasibility of this treatment using the original Kirkwood schedule of 52 weeks, with appropriate dose modification, until unacceptable toxicity or progression of disease.
  • From 23rd February 1998 until 29th July 2002, 26 patients were treated (mean age 45 years; range 25-70) with high-dose interferon-alpha2b adjuvant therapy.
  • All patients were in stage IIB/III of the new American Joint Committee on Cancer (AJCC) classification.
  • The patients lost to follow-up refused to continue therapy for toxicity related treatment: one of them was disease free, whereas one was relapsed.
  • Among the patients, the maximal DFS is, at the time of writing, 59 months.
  • Now our attention is on therapy tolerability.
  • As a result of these reported toxicities, of 23 patients evaluable with regard to the protocol, 12 underwent dose reductions, six suspended treatment for disease progression, eight delayed treatment for toxicity, two interrupted treatment indefinitely for unacceptable toxicity or refused treatment, two refused to continue, two patients had no delay in treatment and three did not receive any delay or dose reduction.
  • Of three patients still in therapy, just one has so far received a delay in treatment.
  • Overall, only four patients (17%) interrupted therapy for toxicity related events, whereas 83% continued with the expected program: 52 weeks of therapy with appropriate dose modifications.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Interferon-alpha / administration & dosage. Interferon-alpha / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Tolerance. Feasibility Studies. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Prognosis. Recurrence. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15057049.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  •  go-up   go-down


19. Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M: Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol; 2004 Jan 1;22(1):53-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
  • PURPOSE: To evaluate low-dose extended duration interferon alfa-2a as adjuvant therapy in patients with thick (> or = 4 mm) primary cutaneous melanoma and/or locoregional metastases.
  • PATIENTS AND METHODS: In this randomized controlled trial involving 674 patients, the effect of interferon alfa-2a (3 megaunits three times per week for 2 years or until recurrence) on overall survival (OS) and recurrence-free survival (RFS) was compared with that of no further treatment in radically resected stage IIB and stage III cutaneous malignant melanoma.
  • RESULTS: The OS and RFS rates at 5 years were 44% (SE, 2.6) and 32% (SE, 2.1), respectively.
  • Subgroup analysis by disease stage, age, and sex did not show any clear differences between interferon-treated and control groups in either OS or RFS.
  • However, there were 50 withdrawals (15%) from interferon treatment due to toxicity.
  • CONCLUSION: The results from this study, taken in isolation, do not indicate that extended-duration low-dose interferon is significantly better than observation alone in the initial treatment of completely resected high-risk malignant melanoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Interferon-alpha / administration & dosage. Interferon-alpha / therapeutic use. Melanoma / drug therapy. Melanoma / surgery. Skin Neoplasms / drug therapy. Skin Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Affect / drug effects. Age Factors. Aged. Aged, 80 and over. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Fatigue / chemically induced. Female. Humans. Male. Middle Aged. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2004 Jan 1;22(1):7-10 [14665612.001]
  • [CommentIn] J Clin Oncol. 2004 Jan 1;22(1):11-4 [14665613.001]
  • (PMID = 14665609.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  •  go-up   go-down


20. Schachter J, Brenner B, Fenig E, Gutman R, Sulkes A, Gutman H: Patterns of failure in patients with malignant melanoma treated with high-dose interferon-alpha2b in the adjuvant setting. Melanoma Res; 2003 Feb;13(1):93-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure in patients with malignant melanoma treated with high-dose interferon-alpha2b in the adjuvant setting.
  • The aim of this prospective study was to record the pattern of failure associated with high-dose interferon-alpha2b (IFN) adjuvant therapy after surgery.
  • It included 55 consecutive patients with stage IIB and III melanoma (median age 50 years) rendered disease-free by surgery but considered at high risk for relapse from a tertiary referral, university-affiliated medical centre.
  • Intervention consisted of IFN 20 mU/m(2) per day intravenously, 5 days a week for 4 weeks, followed by subcutaneous IFN 10 mU/m(2) per day three times a week for 48 weeks.
  • Treatment was stopped at completion of protocol, at disease progression or due to unacceptable toxicity.
  • Dose modification followed treatment-related toxicity.
  • Twenty-six of the 55 patients (47%) relapsed: 14 during treatment and 12 after completion of the protocol.
  • Eighteen of these 26 patients (69%) relapsed initially in a single organ, most commonly in soft tissue or the CNS.
  • Patients treated for stage IIB disease fared better than those treated for stage III disease, regardless of whether the regional metastases were microscopic or palpable.
  • IFN seems to be more commonly associated with a single-organ/single-metastasis pattern of failure, and more soft tissue and CNS relapses.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Interferon-alpha / administration & dosage. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Disease Progression. Female. Humans. Infusions, Intravenous. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prospective Studies. Recombinant Proteins. Survival Rate. Treatment Failure

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12569291.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


21. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH: High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol; 2000 Jun;18(12):2444-58
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
  • PURPOSE: Pivotal trial E1684 of adjuvant high-dose interferon alfa-2b (IFNalpha2b) therapy in high-risk melanoma patients demonstrated a significant relapse-free and overall survival (RFS and OS) benefit compared with observation (Obs).
  • PATIENTS AND METHODS: A prospective, randomized, three-arm, intergroup trial evaluated the efficacy of high-dose IFNalpha2b (HDI) for 1 year and low-dose IFNalpha2b (LDI) for 2 years versus Obs in high-risk (stage IIB and III) melanoma with RFS and OS end points.
  • Neither HDI nor LDI has demonstrated an OS benefit compared with Obs at this time.
  • An analysis of salvage therapy for patients who relapsed on E1690 demonstrated that a significantly larger proportion of patients in the Obs arm received IFNalpha-containing salvage therapy compared with the HDI arm; this therapy was unavailable to patients during E1684, and patients with undissected regional nodes were not included in E1684.
  • This study did not specify therapy at recurrence.
  • Analysis of treatments received at recurrence demonstrated significantly more frequent use of IFNalpha2b at relapse from Obs than from HDI, which may have confounded interpretation of the survival benefit of assigned treatments in E1690.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Interferon-alpha / administration & dosage. Melanoma / drug therapy
  • [MeSH-minor] Aged. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Prospective Studies. Recombinant Proteins. Risk Factors. Salvage Therapy. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2001 Feb 15;19(4):1226-8 [11181688.001]
  • (PMID = 10856105.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10CA392294
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 43K1W2T1M6 / interferon alfa-2b
  •  go-up   go-down


22. Koskivuo IO, Seppänen MP, Suominen EA, Minn HR: Whole body positron emission tomography in follow-up of high risk melanoma. Acta Oncol; 2007;46(5):685-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole body positron emission tomography in follow-up of high risk melanoma.
  • The aim of this study was to determine the clinical impact of whole body positron emission tomography (FDG PET) to detect clinically silent metastases in the follow-up of patients with high risk melanoma.
  • FDG PET was performed to 30 asymptomatic melanoma patients (AJCC stage IIB-IIIC) 7-24 months after the primary surgery and sentinel node biopsy.
  • The positive PET finding had an impact on treatment decisions in every case: three patients underwent surgical resection and four patients received chemotherapy or interferon.
  • The mean follow-up time was 27 months (range, 12-48 months) and during that time the other 23 patients with true negative FDG PET were disease-free.
  • In conclusion, whole body FDG PET is a valuable follow-up tool in high risk melanoma to diagnose recurrences and to select the patients, who are suitable for surgical metastasectomy.
  • [MeSH-major] Melanoma / radionuclide imaging. Melanoma / secondary. Positron-Emission Tomography. Skin Neoplasms / pathology. Whole Body Imaging

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17562446.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


23. Moschos SJ, Odoux C, Land SR, Agarwala S, Friedland D, Volker KM, Sidor C, Wong M, Kirkwood JM: Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res; 2007 Jun;17(3):193-200
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents.
  • In patients with stage IIB-III disease, adjuvant high-dose interferon-alpha2b has shown clinical benefit, although metastatic melanoma is currently without any known survival-prolonging therapy.
  • Angiogenesis has been considered important in melanoma progression, and endostatin is an angiogenesis inhibitor with antitumor activity that has shown promising results in murine model systems, prompting investigation of a formulation of rh-Endostatin (EntreMed, Rockville, Maryland, USA) alone and with interferon in metastatic melanoma.
  • Patients were randomly assigned to receive interferon alpha2b (Schering-Plough) 10 million units/m(2) subcutaneously three times a week plus rh-Endostatin 45 mg/m(2) subcutaneously every 12 h (arm A) vs. rh-Endostatin alone (arm B).
  • No antitumor responses were observed, and no significant differences were noted in time to progression or overall survival.
  • Two patients had stable disease enduring more than 30 weeks on treatment.
  • Serum endostatin levels increased significantly 4 weeks after treatment in both groups.
  • Basic fibroblast growth factor levels in urine were significantly lower following treatment in patients on arm B (P=0.043).
  • The percentage of circulating endothelial cells was increased in five evaluable patients 4 weeks after treatment.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17505265.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / P30 CA4790413
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Endostatins; 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


24. Domingo-Domènech J, Molina R, Castel T, Montagut C, Puig S, Conill C, Martí R, Vera M, Auge JM, Malvehy J, Grau JJ, Gascon P, Mellado B: Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon--comparison with tyrosinase rt-PCR. Oncology; 2005;68(4-6):341-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon--comparison with tyrosinase rt-PCR.
  • OBJECTIVE: To study the clinical value of the determination of serum S-100 protein as a single tumor marker or in combination with tyrosinase RT-PCR in patients with melanoma receiving adjuvant interferon.
  • RESULTS: One hundred and six patients (stage IIA, 27; IIB, 19; III, 49; and IV, 11) were included in the study.
  • In the univariate analysis, under treatment S-100 > or =0.15 microg/l and a positive RT-PCR correlated with a lower disease-free survival and overall survival (OS).
  • In the multivariate analysis, clinical stage, under therapy positive RT-PCR and S-100 levels > or =0.15 mug/ml, were independent prognostic factors for OS.
  • When both techniques where combined, a positive RT-PCR indicated a poorer clinical outcome only in patients with S-100 <0.15 microg/l.
  • CONCLUSIONS: S-100 > or =0.15 microg/l and a positive RT-PCR during adjuvant interferon therapy indicate a high risk of death in resected melanoma patients.
  • S-100 determination has a higher positive predictive value than RT-PCR, while tyrosinase RT-PCR adds prognostic information in patients with S-100 <0.15 microg/l.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Melanoma / blood. Monophenol Monooxygenase / genetics. S100 Proteins / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Recombinant Proteins. Reverse Transcriptase Polymerase Chain Reaction. Skin Neoplasms / blood. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 S. Karger AG, Basel
  • (PMID = 16020961.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Interferon-alpha; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Recombinant Proteins; 0 / S100 Proteins; 99210-65-8 / interferon alfa-2b; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


25. Rao UN, Ibrahim J, Flaherty LE, Richards J, Kirkwood JM: Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol; 2002 Apr 15;20(8):2053-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690.
  • PATIENTS AND METHODS: E1690 included 642 patients with American Joint Committee on Cancer stage IIB or III cutaneous melanoma.
  • Patients were randomized into high- and low-dose rIFN alpha-2b treatment arms and an observation arm.
  • RESULTS: Ulceration, mitotic activity, thickness, and size of tumor-bearing lymph nodes did not show a statistically significant correlation with either OS or RFS across all treatment arms.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Melanoma / drug therapy. Melanoma / pathology
  • [MeSH-minor] Humans. Lymphatic Metastasis. Mitotic Index. Neoplasm Staging. Recombinant Proteins. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology. Survival Analysis. Ulcer

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11956265.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA39229; United States / NCI NIH HHS / CA / CA66636
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


26. Guillot B, Blazquez L, Bessis D, Dereure O, Guilhou JJ: A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma. Dermatology; 2004;208(1):49-54
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma.
  • OBJECTIVES: A prospective study was designed to evaluate the incidence and clinical pattern of cutaneous side effects in a cohort of patients receiving adjuvant therapy with low-dose interferon for malignant melanoma.
  • MATERIAL AND METHODS: A cohort of 33 patients with stage IIA and IIB melanoma treated with low-dose alpha-interferon (3 MIU 3 times a week for 18 months) were prospectively enrolled in a single-center study.
  • The patients responded to a questionnaire on their medical history and were systematically examined for any cutaneous lesions before treatment and every 3 months afterwards.
  • CONCLUSION: Cutaneous adverse events during adjuvant immunotherapy of melanoma with low-dose alpha-interferon seem to be frequent but do not result in treatment discontinuation.
  • A good awareness of these side effects may be useful for a more accurate survey and clinical management of patients receiving this treatment.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Head and Neck Neoplasms / drug therapy. Interferon-alpha / adverse effects. Melanoma / drug therapy. Skin Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 S. Karger AG, Basel
  • (PMID = 14730237.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  •  go-up   go-down


27. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U, Eastern Cooperative Oncology Group: A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res; 2004 Mar 1;10(5):1670-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.
  • PURPOSE: Nearly 2000 patients with stage IIB and III melanoma have participated in four multicenter, randomized trials, conducted by the Eastern Cooperative Oncology Group and the Intergroup, investigating adjuvant high-dose IFN-alpha 2b therapy.
  • The objectives of this study were to update the analyses of each individual trial and to analyze prognostic factors and treatment effects based on pooled data.
  • Analysis of treatment effects versus observation (Obs) was based on data from 713 patients randomized to high-dose IFN-alpha 2b (HDI) or Obs in Trials E1684 and E1690.
  • CONCLUSIONS: In patients with high-risk resected melanoma, HDI is effective adjuvant therapy with strong evidence for improved RFS and evidence for moderate improvement in OS based on two prospective randomized studies but not the pooled analysis.
  • Analyses of predictors of relapse and response are now needed to improve the therapeutic value of this modality.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Interferon-alpha / therapeutic use. Melanoma / drug therapy
  • [MeSH-minor] Adult. Aged. Clinical Trials as Topic. Confidence Intervals. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Recombinant Proteins. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15014018.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-23318
  • [Publication-type] Clinical Trial; Journal Article; Meta-Analysis; Randomized Controlled Trial; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


28. Slingluff CL Jr, Petroni GR, Yamshchikov GV, Hibbitts S, Grosh WW, Chianese-Bullock KA, Bissonette EA, Barnd DL, Deacon DH, Patterson JW, Parekh J, Neese PY, Woodson EM, Wiernasz CJ, Merrill P: Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol; 2004 Nov 15;22(22):4474-85
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule.
  • PURPOSE: A phase II trial was performed to test whether systemic low-dose interleukin-2 (IL-2) augments T-cell immune responses to a multipeptide melanoma vaccine.
  • Forty patients with resected stage IIB-IV melanoma were randomly assigned to vaccination with four gp100- and tyrosinase-derived peptides restricted by human leukocyte antigen (HLA) -A1, HLA-A2, and HLA-A3, and a tetanus helper peptide plus IL-2 administered daily either beginning day 7 (group 1), or beginning day 28 (group 2).
  • RESULTS: T-cell responses to the melanoma peptides were observed in 37% of PBL and 38% of SINs in group 1, and in 53% of PBL and 83% of SINs in group 2.
  • The magnitude of T-cell response was higher in group 2.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cancer Vaccines / immunology. Cancer Vaccines / pharmacology. Interleukin-2 / pharmacology. Melanoma / drug therapy. Melanoma / immunology. Skin Neoplasms / drug therapy. Skin Neoplasms / immunology. Vaccines, Subunit / immunology. Vaccines, Subunit / pharmacology
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Drug Administration Schedule. Female. HLA Antigens / immunology. Humans. Male. Membrane Glycoproteins / immunology. Middle Aged. Neoplasm Proteins / immunology. Treatment Outcome. Tyrosine / immunology. gp100 Melanoma Antigen

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Aug 1;23(22):5265-7; author reply 5267-8 [16051975.001]
  • (PMID = 15542798.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR00847; United States / NCI NIH HHS / CA / P30 CA44579; United States / NCI NIH HHS / CA / R01 CA57653
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 0 / HLA Antigens; 0 / Interleukin-2; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / PMEL protein, human; 0 / Vaccines, Subunit; 0 / gp100 Melanoma Antigen; 42HK56048U / Tyrosine
  •  go-up   go-down


29. Pectasides D, Dafni U, Bafaloukos D, Skarlos D, Polyzos A, Tsoutsos D, Kalofonos H, Fountzilas G, Panagiotou P, Kokkalis G, Papadopoulos O, Castana O, Papadopoulos S, Stavrinidis E, Vourli G, Ioannovich J, Gogas H: Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol; 2009 Feb 20;27(6):939-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.
  • PURPOSE: A high-dose interferon alfa (IFN-alpha) regimen as reported in E1684 was unique for the incorporation of an induction phase of maximally tolerated dosages of intravenous (IV) therapy for the initial 4 weeks.
  • PATIENTS AND METHODS: We conducted a prospective randomized study of IV induction therapy versus a full year of high-dose IFN, with primary end points of RFS and OS for patients with stage IIB, IIC, and III melanoma, within 56 days of curative surgery.
  • Patients were randomly assigned to receive IFN-alpha-2b 15 x 10(6) U/m2 IV x 5/7 days weekly x 4 weeks (arm A) versus the same regimen followed by IFN-alpha-2b 10 x 10(6) U (flat dose) administered subcutaneously three times a week for 48 weeks (arm B).
  • CONCLUSION: There were no significant differences in OS and RFS between the regimens of 1 month and 1 year of treatment.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Interferon-alpha / administration & dosage. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Recombinant Proteins. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Sep 1;27(25):e82-3; author reply e84 [19635995.001]
  • [CommentIn] J Clin Oncol. 2009 Aug 20;27(24):e70; author reply e71 [19620476.001]
  • (PMID = 19139440.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


30. Mitchell MS: Cancer vaccines, a critical review--Part I. Curr Opin Investig Drugs; 2002 Jan;3(1):140-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vaccines augment already established tumor immunity, are far more specific against the tumor than cytokines, have little or no toxicity, and thus may easily be combined with other types of immunotherapy.
  • Melanoma vaccines have received the most attention thus far.
  • Among the several vaccines in clinical trials are whole cell lysates, such as Melacine, hapten-treated autologous melanoma cells (M-Vax) and irradiated allogeneic cells (CancerVax).
  • Controlled trials of Melacine indicate prolongation of survival in patients with resected stage IIB disease, particularly those with one or more of the following HLA class I alleles: HLA-A2 or -A28 (-A6802), HLA-B12, -44 or -45, and HLA-C3.
  • A combination of interferon-alpha2b and Melacine appears to enhance the anti-tumor response in advanced (stage IV) disease, and is being tested in a large randomized controlled trial in resected stage III disease.
  • An irradiated autologous colon carcinoma vaccine has improved relapse-free survival in resected stage II disease (Dukes B) in a controlled trial.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Humans. Melanoma / drug therapy. Melanoma / immunology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12054065.001).
  • [ISSN] 1472-4472
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines
  • [Number-of-references] 32
  •  go-up   go-down


31. Gogas H, Bafaloukos D, Ioannovich J, Skarlos D, Polyzos A, Fountzilas G, Kalofonos HP, Aravantinos G, Tsoutsos D, Panagiotou P, Frangia K, Petrakopoulou T, Pectasides D, Hellenic Coperative Oncology Group: Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study. Anticancer Res; 2004 May-Jun;24(3b):1947-52
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: High-dose interferon alfa-2b (IFN-alpha2b) as adjuvant therapy for melanoma is associated with substantial dose-limiting toxicity.
  • PATIENTS AND METHODS: The Hellenic Cooperative Oncology Group is conducting a multicenter, randomized trial of 1-month i.v. induction versus 1 year of adjuvant IFN-alpha2b therapy in patients with stage IIB/III melanoma.
  • Adverse events reported by the first 200 patients to complete therapy are described.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Interferon-alpha / administration & dosage. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging. Recombinant Proteins. Remission Induction

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15274382.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


32. Chianese-Bullock KA, Woodson EM, Tao H, Boerner SA, Smolkin M, Grosh WW, Neese PY, Merrill P, Petroni GR, Slingluff CL Jr: Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J Immunother; 2005 Jul-Aug;28(4):412-9
Hazardous Substances Data Bank. D-MANNITOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this investigation was to evaluate the occurrence of autoimmune toxicities associated with the administration of low-dose IL-2 in conjunction with vaccines for melanoma.
  • Ninety-three patients with stage IIB, III, or IV melanoma were enrolled in three clinical trials and received anti-melanoma vaccines on days 1, 8, 15, 29, 36, and 43.
  • Overall, autoimmune toxicities affecting several organ systems were observed in patients receiving melanoma vaccines in conjunction with low-dose IL-2.
  • None of these toxicities caused major long-term effects, though one was acutely life-threatening and others contributed to treatment-related morbidity.
  • [MeSH-major] Autoimmunity / immunology. Cancer Vaccines / immunology. Interleukin-2 / immunology. Melanoma / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / immunology. Dendritic Cells / immunology. Dose-Response Relationship, Drug. Eye Diseases / chemically induced. Eye Diseases / pathology. Female. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Humans. Hyperglycemia / chemically induced. Hyperglycemia / drug therapy. Hyperglycemia / pathology. Immunity, Cellular / immunology. Injections, Subcutaneous. Interferon-gamma / metabolism. Male. Mannitol / analogs & derivatives. Mannitol / immunology. Membrane Glycoproteins / immunology. Middle Aged. Monophenol Monooxygenase / immunology. Neoplasm Proteins / immunology. Oleic Acids / immunology. Peptide Fragments / immunology. T-Lymphocytes / immunology. T-Lymphocytes / metabolism. Thyroiditis, Autoimmune / chemically induced. Thyroiditis, Autoimmune / drug therapy. Thyroiditis, Autoimmune / pathology. Treatment Outcome. Tumor Cells, Cultured. Vitiligo / chemically induced. Vitiligo / immunology. Vitiligo / pathology. gp100 Melanoma Antigen

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16000961.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR00847; United States / NCI NIH HHS / CA / P30CA44579; United States / NCI NIH HHS / CA / R01 CA57983; United States / NCI NIH HHS / CA / R01 CA78519; United States / NCI NIH HHS / CA / R21 CA89937
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Interleukin-2; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / Oleic Acids; 0 / PMEL protein, human; 0 / Peptide Fragments; 0 / gp100 Melanoma Antigen; 0 / montanide ISA 51; 3OWL53L36A / Mannitol; 82115-62-6 / Interferon-gamma; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


33. Bleomycin--electrical pulse delivery: electroporation therapy-bleomycin--Genetronics; MedPulser-bleomycin--Genetronics. Drugs R D; 2004;5(5):293-6
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bleomycin--electrical pulse delivery: electroporation therapy-bleomycin--Genetronics; MedPulser-bleomycin--Genetronics.
  • Genetronics Biomedical is using its electroporation therapy technology to deliver bleomycin to tumour cells for the treatment of cancer.
  • Genetronics have developed the MedPulser Electroporation Therapy System, which consists of an electrical pulse generator and disposable electrode applicators.
  • After the field is discontinued, the pores close, trapping the therapeutic molecules inside the target cells.
  • Genetronics is seeking a licensing partner for the use of electroporation for the delivery of drugs in chemotherapy.
  • In 1997, Genetronics entered an agreement with Abbott Laboratories for the manufacture of bleomycin for use in the US in its MedPulsar system after regulatory approval had been granted for its use in the treatment of solid tumours.
  • The MedPulsar Electroporation Therapy System with bleomycin is currently in phase III pivotal studies in the US as a treatment for recurrent and second primary squamous cell carcinomas of the head and neck.
  • Genetronics received approval for the Electroporation Therapy system as a device in March 1999 when it achieved CE Mark certification.
  • In February 2004, Genetronics announced that it had completed a Special Protocol Assessment review process with the US FDA for two new trials that will compare bleomycin electroporation therapy to surgery.
  • The primary endpoint will be tissue and function preservation rather than survival.
  • In June 2004, Genetronics was granted fast-track status for its MedPulsar Electroporation Therapy System clinical development programme for patients with head and neck cancer.
  • This includes a phase III trial for late-stage, recurrent head and neck cancer in combination with the normal standard of treatment compared with normal standard of treatment alone.
  • Interim results from this trial had suggested bleomycin electroporation therapy demonstrated local tumour control and preservation of organ function, as well as non-inferiority when compared with surgery.
  • Prior clinical trials established the safety and performance of the MedPulser System for the treatment of SCCHN, leading to approval for sale in the EU based on achieving the CE Mark.
  • The bleomycin delivery system has completed phase IIB trials in the US, Canada and Europe in patients with squamous cell carcinoma of the head and neck who have failed conventional therapies.
  • The therapy is also being used in France in patients with cancers of the head and neck, liver (metastatic) and melanoma.
  • US patent 6,748,265 covers its trans-surface drug and gene delivery technology and provides additional proprietary rights for an apparatus and method to deliver genes, drugs and other molecules through tissue surfaces.
  • The second US patent, 6,746,441, pertains to the field of ex vivo therapies and covers the introduction of molecules into cells by electroporation, either in a continuous-flow or batch mode, with a variable electric field orientation.
  • In July 2004, Genetronics received a US patent (no. 6,763,264) covering methods for the in vivo delivery of a recombinant expression vector (DNA) or a pharmaceutical agent into tissue cells, and a method for the therapeutic application of electroporation to a patient to introduce macromolecules.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / administration & dosage. Bleomycin / therapeutic use. Electroporation / instrumentation
  • [MeSH-minor] Carcinoma, Squamous Cell / drug therapy. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Head and Neck Neoplasms / drug therapy. Humans. Patents as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Adis Data Information BV
  • (PMID = 15357628.001).
  • [ISSN] 1174-5886
  • [Journal-full-title] Drugs in R&D
  • [ISO-abbreviation] Drugs R D
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


34. Health Quality Ontario: Extracorporeal photophoresis: an evidence-based analysis. Ont Health Technol Assess Ser; 2006;6(6):1-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the effectiveness, safety and cost-effectiveness of extracorporeal photophoresis (ECP) for the treatment of refractory erythrodermic cutaneous T cell lymphoma (CTCL) and refractory chronic graft versus host disease (cGvHD).
  • BACKGROUND: CUTANEOUS T CELL LYMPHOMA: Cutaneous T cell lymphoma (CTCL) is a general name for a group of skin affecting disorders caused by malignant white blood cells (T lymphocytes).
  • The relative frequency and disease-specific 5-year survival of 1,905 primary cutaneous lymphomas classified according to the World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification (Appendix 1).
  • Cutaneous T cell lymphoma has an annual incidence of approximately 0.4 per 100,000 and it mainly occurs in the 5(th) to 6(th) decade of life, with a male/female ratio of 2:1.
  • Mycosis fungoides is an indolent lymphoma with patients often having several years of eczematous or dermatitic skin lesions before the diagnosis is finally established.
  • Early in the disease biopsies are often difficult to interpret and the diagnosis may only become apparent by observing the patient over time.
  • Most patients will live normal lives and experience skin symptoms without serious complications.
  • A particular syndrome in these patients involves erythroderma (intense and usually widespread reddening of the skin from dilation of blood vessels, often preceding or associated with exfoliation), and circulating tumour cells.
  • CHRONIC GRAFT VERSUS HOST DISEASE: Allogeneic hematopoietic cell transplantation (HCT) is a treatment used for a variety of malignant and nonmalignant disease of the bone marrow and immune system.
  • The procedure is often associated with serious immunological complications, particularly graft versus host disease (GvHD).
  • Of the patients with extensive disease, approximately 60% will respond to treatment and eventually be able to discontinue immunosuppressive therapy.
  • The remaining patients will develop opportunistic infection, or require prolonged treatment with immunosuppressive agents.
  • The extent of involvement varies significantly from mild involvement limited to a few patches of skin to severe involvement of numerous organ systems and profound immunodeficiency.
  • The most commonly involved tissues are the skin, liver, mouth, and eyes.
  • Patients with limited disease have localized skin involvement, evidence of liver dysfunction, or both, whereas those with more involvement of the skin or involvement of other organs have extensive disease.
  • TREATMENT:   CUTANEOUS T CELL LYMPHOMA: The optimal management of MF is undetermined because of its low prevalence, and its highly variable natural history, with frequent spontaneous remissions and exacerbations and often prolonged survival.
  • Nonaggressive approaches to therapy are usually warranted with treatment aimed at improving symptoms and physical appearance while limiting toxicity.
  • Given that multiple skin sites are usually involved, the initial treatment choices are usually topical or intralesional corticosteroids or phototherapy using psoralen (a compound found in plants which make the skin temporarily sensitive to ultraviolet A) (PUVA).
  • Repeated courses are usually required which may lead to an increased risk of both melanoma and nonmelanoma skin cancer.
  • "Second line" therapy for early stage disease is often topical chemotherapy, radiotherapy or total skin electron beam radiation (TSEB).
  • Treatment of advanced stage (IIB-IV) MF usually consists of topical or systemic therapy in refractory or rapidly progressive SS.
  • Bone marrow transplantation and peripheral blood stem cell transplantation have been used to treat many malignant hematologic disorders (e.g., leukemias) that are refractory to conventional treatment.
  • Reports on the use of these procedures for the treatment of CTCL are limited and mostly consist of case reports or small case series.
  • CHRONIC GRAFT VERSUS HOST DISEASE: Patients who develop cGvHD require reinstitution of immunosuppressive medication (if already discontinued) or an increase in dosage and possibly addition of other agents.
  • The current literature regarding cGvHD therapy is less than optimal and many recommendations about therapy are based on common practices that await definitive testing.
  • Numerous salvage therapies have been considered in patients with refractory cGvHD, including ECP.
  • Due to uncertainty around salvage therapies, Bhushan and Collins suggested that ideally, patients with refractory cGvHD should be entered into clinical trials.
  • Two Ontario expert consultants jointly estimated that there may be approximately 30 new erythrodermic treatment resistant CTCL patients and 30 new treatment resistant cGvHD patients per year who are unresponsive to other forms of therapy and may be candidates for ECP.
  • Extracorporeal photopheresis is a procedure that was initially developed as a treatment for CTCL, particularly SS.
  • The lymphocyte layer is treated with methoxsalen (a drug that sensitizes the lymphocytes to light) and exposed to UVA, following which the lymphocytes are returned to the patient.
  • Photosensitization is achieved by administering methoxsalen to the patient orally 2 hours before the procedure, or by injecting methoxsalen directly ino the leucocyte rich fraction.
  • The latter approach avoids potential side effects such as nausea, and provides a more consistent drug level within the machine.
  • In general, from the time the intravenous line is inserted until the white blood cells are returned to the patient takes approximately 2.5-3.5 hours.
  • For CTCL, the treatment schedule is generally 2 consecutive days every 4 weeks for a median of 6 months.
  • For cGvHD, an expert in the field estimated that the treatment schedule would be 3 times a week for the 1(st) month, then 2 consecutive days every 2 weeks after that (i.e., 4 treatments a month) for a median of 6 to 9 months.
  • REGULATORY STATUS: The UVAR XTS Photopheresis System is licensed by Health Canada as a Class 3 medical device (license # 7703) for the "palliative treatment of skin manifestations of CTCL."
  • It is not licensed for the treatment of cGvHD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1998 Feb;38(2 Pt 1):207-20 [9486676.001]
  • [Cites] J Am Acad Dermatol. 1996 Oct;35(4):573-9 [8859287.001]
  • [Cites] J Cutan Med Surg. 2003 Jul-Aug;7(4 Suppl):13-7 [12958702.001]
  • [Cites] Cancer. 1988 Oct 15;62(8):1658-61 [3167782.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1217-23 [12714516.001]
  • [Cites] J Am Acad Dermatol. 1992 Sep;27(3):427-33 [1401279.001]
  • [Cites] N Engl J Med. 1987 Feb 5;316(6):297-303 [3543674.001]
  • [Cites] Arch Dermatol. 2002 Oct;138(10):1347-50 [12374541.001]
  • [Cites] J Am Acad Dermatol. 1992 Nov;27(5 Pt 1):729-36 [1430395.001]
  • [Cites] Cancer Treat Rep. 1979 Apr;63(4):701-7 [376140.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1404-11 [12663734.001]
  • [Cites] Ann Intern Med. 1988 Sep 1;109(5):372-82 [3408055.001]
  • [Cites] Arch Dermatol. 1998 Aug;134(8):1001-5 [9722731.001]
  • [Cites] J Am Acad Dermatol. 2001 Feb;44(2):253-60 [11174383.001]
  • [Cites] J Am Acad Dermatol. 2000 Aug;43(2 Pt 1):263-71 [10906649.001]
  • [Cites] Br J Dermatol. 2000 Jan;142(1):16-21 [10651689.001]
  • [Cites] Bone Marrow Transplant. 2005 Jun;35(12):1187-93 [15852025.001]
  • [Cites] BMJ. 2004 Jun 19;328(7454):1490 [15205295.001]
  • [Cites] Cancer. 2001 Oct 1;92(7):1745-52 [11745245.001]
  • [Cites] J Am Acad Dermatol. 1996 Dec;35(6):935-45 [8959953.001]
  • [Cites] Yale J Biol Med. 1989 Nov-Dec;62(6):629-38 [2534648.001]
  • [Cites] J Cutan Pathol. 1997 May;24(5):286-91 [9194581.001]
  • [Cites] Br J Dermatol. 2006 Jan;154(1):7-20 [16403088.001]
  • [Cites] Cancer. 1981 Jun 1;47(11):2671-7 [7260860.001]
  • [Cites] Ann Intern Med. 1994 Oct 15;121(8):592-602 [8085692.001]
  • [Cites] Bone Marrow Transplant. 2003 Mar;31(6):459-65 [12665841.001]
  • [Cites] Lancet. 1997 Jul 5;350(9070):32-3 [9217723.001]
  • [Cites] Int J Artif Organs. 2000 Jan;23(1):55-62 [12118838.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1298-301 [11520774.001]
  • [Cites] JAMA. 2003 Nov 19;290(19):2599-603 [14625337.001]
  • [Cites] Blood. 1987 Mar;69(3):841-9 [3493044.001]
  • [Cites] Br J Haematol. 2005 Jul;130(2):271-5 [16029456.001]
  • [Cites] Arch Dermatol. 2002 Aug;138(8):1054-60 [12164743.001]
  • [Cites] J Am Acad Dermatol. 1993 Apr;28(4):580-4 [8463458.001]
  • [Cites] Lancet. 1997 Sep 20;350(9081):886 [9310623.001]
  • [Cites] N Engl J Med. 1989 Dec 28;321(26):1784-90 [2594037.001]
  • [Cites] Br J Dermatol. 2004 Feb;150(2):327-36 [14996105.001]
  • [Cites] J Am Acad Dermatol. 2000 Jul;43(1 Pt 1):54-60 [10863224.001]
  • [Cites] Lancet. 2001 Mar 17;357(9259):820-1 [11265946.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3074-80 [16368882.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):118-27 [12823353.001]
  • [Cites] Clin Exp Dermatol. 2004 May;29(3):231-6 [15115499.001]
  • [Cites] J Am Acad Dermatol. 1996 Dec;35(6):946-57 [8959954.001]
  • [Cites] Ann N Y Acad Sci. 1991 Dec 30;636:171-7 [1793207.001]
  • [Cites] J Am Acad Dermatol. 1997 Mar;36(3 Pt 1):460-6 [9091480.001]
  • [Cites] Br J Dermatol. 2005 Jul;153(1):1-5 [16033336.001]
  • (PMID = 23074497.001).
  • [Journal-full-title] Ontario health technology assessment series
  • [ISO-abbreviation] Ont Health Technol Assess Ser
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3379535
  •  go-up   go-down


35. Mismatched double-stranded RNA: polyI:polyC12U. Drugs R D; 2004;5(5):297-304
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ampligen, currently under development by Hemispherx Biopharma in the US, acts on the immunological system through T-lymphocyte stimulation and is indicated for the treatment of chronic fatigue syndrome and acquired immunodeficiency deficiency syndrome (AIDS), as part of the combined therapy.
  • In February 2004, Fujisawa Deutschland GmbH, a subsidiary of Fujisawa Pharmaceutical Co., entered into an option agreement with Hemispherx Biopharma with the intent of becoming a distributor for Ampligen for the potential treatment of chronic fatigue syndrome in Germany, Switzerland and Austria.
  • The agreement stipulates that the Guangdong Medicine Group Corporation (GMC) will conduct clinical trials with Ampligen for the treatment of HIV.
  • In May 2003, Hemispherx Biopharma and the Center for Cell and Gene Therapy entered into a research project agreement that will see Ampligen implemented in a protocol used in patients with relapsed EBV-positive Hodgkin's Lymphoma.
  • In March 2002, Esteve and Hemispherx Biopharma entered into a collaborative agreement under which Esteve will be the sole distributor of Ampligen in Spain, Portugal and Andorra for the treatment of chronic fatigue syndrome.
  • Under this agreement, in addition to other terms, Esteve will also collaborate in the drug product development by conducting clinical studies in Spain in patients coinfected with HIV/HCV.
  • In July 2001 Hemispherx Biopharma announced that it had formed a strategic alliance with Empire Health Resources for clinical trials of Ampligen in the treatment of HIV and hepatitis C virus infections.
  • Hemispherx and AOP Orphan Pharmaceuticals have signed a marketing agreement for Ampligen for the treatment of chronic fatigue syndrome for Austria, the Czech Republic, Poland and Hungary.
  • In the US, Ampligen has been granted orphan drug status for the treatment of AIDS, renal cell carcinoma (phase II, completed), chronic fatigue syndrome (phase III) and invasive/metastatic malignant melanoma (phase II).
  • Previously, Hemispherx submitted an application to the EMEA for the approval of Ampligen for the treatment of chronic fatigue syndrome; the first stage of th;) for the treatment of chronic fatigue syndrome; the first stage of the regulatory review has been cleared.
  • In 2000, Hemispherx Europe (Hemispherx) obtained orphan drug status for Ampligen for the treatment of chronic fatigue syndrome in the EU, providing Hemispherx with 10 years of marketing exclusivity following the launch of the drug, as well as potential financial research benefits for the agent.
  • In February 2000, Crystaal Corporation (now Biovail Pharmaceuticals Canada) acquired exclusive marketing rights to Ampligen in Canada, where it submitted an NDA for the agent for the treatment of chronic fatigue syndrome.
  • In the meantime, Ampligen has been available since May 1996 under the Canadian Emergency Drug Release Programme for the treatment of chronic fatigue syndrome and immune dysfunction syndrome by Rivex Pharma (Helix BioPharma).
  • Bioclones has initiated clinical studies with Ampligen for the treatment of chronic fatigue syndrome in Australia.
  • Clinical treatment programmes for chronic fatigue syndrome in other Pacific Rim countries are planned.
  • Hemispherx has developed a 'ready-to-use' liquid formulation of the drug and has begun treating patients with chronic fatigue syndrome in ongoing clinical trials.
  • Hemispherx has also developed an oral version of the drug (Oragen), which is undergoing preclinical evaluation.
  • In February 2001, Hemispherx Biopharma announced that it was initiating phase II/III trials of Ampligen in the treatment of late-stage, multidrug-resistant strains of HIV in the European Union.
  • Patients treated in these studies will have exhausted all other treatment options.
  • In July 2001, Hemispherx stated that Ampligen was being evaluated in a phase IIb trial in patients with HIV in the US.
  • The trial, comprising two studies, REARMI and REARMII (Research/Evaluation of Ampligen for Retroviral Mutations I and II), will evaluate the ability of Ampligen to prevent the emergence of mutated, drug-resistant strains of the virus.
  • 'Several hundred' patients currently on antiretroviral therapy and at risk of viral relapse will be enrolled at centres in Connecticut, New York, Florida and California.
  • A second phase IIb study evaluating the effect of Ampligen on structured treatment interruptions (STI) is also underway.
  • NIH sponsored studies of potential therapies for SARS have identified Ampligen as having unusually high and consistent antiviral activity against human coronavirus, the pathogen implicated as the causative agent of the disease.
  • In May 2004 Hemispherx announced that it had filed an expanded US patent application covering the use of Ampligen for the potential treatment and prevention of severe acute respiratory syndrome (SARS) and dreaded emerging viruses.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Poly I-C / therapeutic use. Poly U / therapeutic use. RNA, Double-Stranded / therapeutic use. Virus Diseases / drug therapy
  • [MeSH-minor] Animals. Anti-HIV Agents / pharmacology. Anti-HIV Agents / therapeutic use. Base Pair Mismatch. Drug Interactions. Hepatitis B / drug therapy. Humans. Mice. Nervous System Diseases / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Viral Infections.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Adis Data Information BV
  • (PMID = 15357629.001).
  • [ISSN] 1174-5886
  • [Journal-full-title] Drugs in R&D
  • [ISO-abbreviation] Drugs R D
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / RNA, Double-Stranded; 0 / poly(I).poly(c12,U); 24939-03-5 / Poly I-C; 27416-86-0 / Poly U
  •  go-up   go-down


36. Kirkwood JM, Tarhini AA, Moschos SJ, Panelli MC: Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma. Nat Clin Pract Oncol; 2008 Jan;5(1):2-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma.
  • [MeSH-major] Chemotherapy, Adjuvant. Immunologic Factors / therapeutic use. Interferon-alpha / therapeutic use. Melanoma / drug therapy
  • [MeSH-minor] Controlled Clinical Trials as Topic / statistics & numerical data. Cost-Benefit Analysis. Disease-Free Survival. Follow-Up Studies. Humans. Lymphatic Metastasis. Meta-Analysis as Topic. Multicenter Studies as Topic / statistics & numerical data. Neoplasm Staging. Recombinant Proteins. Risk. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Oncol. 2008 Jan;5(1):4-5 [18043604.001]
  • (PMID = 18030300.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


37. Bajetta E: Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma. Nat Clin Pract Oncol; 2008 Jan;5(1):4-5
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
  • [MeSH-major] Chemotherapy, Adjuvant. Immunologic Factors / therapeutic use. Interferon-alpha / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Dacarbazine / therapeutic use. Disease-Free Survival. Follow-Up Studies. Humans. Lymphatic Metastasis. Meta-Analysis as Topic. Multicenter Studies as Topic / statistics & numerical data. Neoplasm Staging. Patient Selection. Quality of Life. Randomized Controlled Trials as Topic / statistics & numerical data. Recombinant Proteins. Risk. Survival Analysis. Treatment Failure

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Nat Clin Pract Oncol. 2008 Jan;5(1):2-3 [18030300.001]
  • (PMID = 18043604.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / Recombinant Proteins; 7GR28W0FJI / Dacarbazine; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down






Advertisement